JP2025511167A - 顔面肩甲上腕型筋ジストロフィー（ｆｓｈｄ）の新規な処置 - Google Patents

顔面肩甲上腕型筋ジストロフィー（ｆｓｈｄ）の新規な処置 Download PDF

Info

Publication number
JP2025511167A
JP2025511167A JP2024557991A JP2024557991A JP2025511167A JP 2025511167 A JP2025511167 A JP 2025511167A JP 2024557991 A JP2024557991 A JP 2024557991A JP 2024557991 A JP2024557991 A JP 2024557991A JP 2025511167 A JP2025511167 A JP 2025511167A
Authority
JP
Japan
Prior art keywords
myostatin
antibody
seq
amino acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511167A5 (enExample
Inventor
ガキ，エレニ
マカイバー，タミー
シチリアーニ・スカルコ，レナータ
ヴァーグナー，キャスリン・レイ
ヨン，ワイ・イン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2025511167A publication Critical patent/JP2025511167A/ja
Publication of JP2025511167A5 publication Critical patent/JP2025511167A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024557991A 2022-04-01 2023-03-30 顔面肩甲上腕型筋ジストロフィー（ｆｓｈｄ）の新規な処置 Pending JP2025511167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166261 2022-04-01
EP22166261.2 2022-04-01
PCT/EP2023/058218 WO2023187022A1 (en) 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd)

Publications (2)

Publication Number Publication Date
JP2025511167A true JP2025511167A (ja) 2025-04-15
JP2025511167A5 JP2025511167A5 (enExample) 2026-04-07

Family

ID=81328333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557991A Pending JP2025511167A (ja) 2022-04-01 2023-03-30 顔面肩甲上腕型筋ジストロフィー（ｆｓｈｄ）の新規な処置

Country Status (11)

Country Link
US (1) US20250171526A1 (enExample)
EP (1) EP4504779A1 (enExample)
JP (1) JP2025511167A (enExample)
KR (1) KR20240165959A (enExample)
CN (1) CN119053619A (enExample)
AU (1) AU2023246859A1 (enExample)
CA (1) CA3255735A1 (enExample)
IL (1) IL315473A (enExample)
MX (1) MX2024011922A (enExample)
TW (1) TW202346345A (enExample)
WO (1) WO2023187022A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026147753A1 (en) * 2024-12-30 2026-07-09 Scholar Rock, Inc. Therapies for muscular dystrophies
US20260199503A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения

Also Published As

Publication number Publication date
MX2024011922A (es) 2024-11-08
EP4504779A1 (en) 2025-02-12
CN119053619A (zh) 2024-11-29
KR20240165959A (ko) 2024-11-25
AU2023246859A1 (en) 2024-09-05
IL315473A (en) 2024-11-01
AU2023246859A9 (en) 2024-09-12
WO2023187022A1 (en) 2023-10-05
US20250171526A1 (en) 2025-05-29
TW202346345A (zh) 2023-12-01
CA3255735A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
AU2020210134B2 (en) Use of myostatin inhibitors and combination therapies
US10882904B2 (en) Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
JP7003354B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP6845012B2 (ja) 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
US9175075B2 (en) Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
JP7008920B2 (ja) 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用
US11208490B2 (en) Methods for the treatment of thyroid eye disease
PT2625199T (pt) Métodos de tratamento de psoríase usando antagonistas de il-17
TW201536318A (zh) 治療偶發性包涵體肌炎之方法
JP2017513882A (ja) 股関節部骨折手術後の身体回復を改善または促進する方法
US20250171526A1 (en) Treatment for Facioscapulohumeral Muscular Dystrophy (FSHD)
JP2004536072A (ja) 種々の疾患の治療のための抗−ｎｇｆ抗体
US20240358704A1 (en) Combined administration
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
KR20220054608A (ko) ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
TW202434633A (zh) 治療甲狀腺眼疾之方法
JP2025176134A (ja) 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
HK40112393A (en) New treatment for facioscapulohumeral muscular dystrophy (fshd)
JP2025529287A (ja) マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
HK40103690A (en) Novel combined administration
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260330